2023 Whitepaper - BayMark Health Services | Leaders in Medication-Assisted Treatment

2023 Opioid Use Disorder Treatment Outcomes Report

Medication-assisted treatment (MAT) is widely recognized as the gold standard of care for the treatment of opioid use disorders (OUD). BayMark Health Services has expanded upon the existing research to further document the efficacy of MAT in treating opioid addiction by introducing new data, including:
  • MAT clinical outcomes for outpatient opioid use disorder
    treatment of approximately 39,000 patients
  • Treatment retention and drug test outcomes
  • Patient health data findings
  • Implications from the Fentanyl crisis
Learn why MAT continues to be a leading treatment protocol for OUD by downloading the whitepaper today!

Download the Whitepaper below!

By clicking the button, you agree to receive information about BayMark. Occasionally we will send updates; be assured we will not sell your information.

Learn about the efficacy of Medication-assisted treatment (MAT) for the treatment of opioid use disorders (OUD) during the COVID-19 pandemic and the widespread Fentanyl crisis.

An overwhelming amount of evidence demonstrates the substantial benefits and effectiveness of MAT, including reductions in overdose deaths and maladaptive health behaviors that increase risk for HIV and Hepatitis C, reduced drug use, and criminal activity. It is also commonly reported that MAT is associated with significant cost reductions in healthcare and the criminal justice system.
This 2023 Opioid Use Disorder Treatment Outcomes Report expands on historical data on the effectiveness of MAT and reports patient demographics and treatment outcomes for a sample of approximately 39,000 patients who received/are receiving outpatient MAT (methadone and buprenorphine) services in BayMark Health Services’ Opioid Treatment Programs and Office-Based Opioid Treatment between 2020 and 2022.
The timeframe of reporting includes the unprecedented COVID-19 pandemic, which contributed to a measurable and sustained impact on treatment outcomes. Moreover, the past few years are associated with rapid increases in Fentanyl use, which has introduced significant challenges for MAT providers.
To our knowledge, this is the largest reported data set of OUD treatment outcomes available today.

BayMark Health Services is dedicated to providing treatment tailored to meet each person regardless of where they are in their recovery journey. BayMark provides a full continuum of care, integrating evidence-based practices, clinical counseling, recovery support, and medical services.

BayMark’s comprehensive addiction treatment programs deliver medically-supervised services for adults in a variety of modalities and settings. As the largest specialty healthcare organization in North America addressing substance use disorders, we provide a continuum of care. We partner with individuals to assess and match them with the treatment that best meets their needs. While our programs focus primarily on the treatment of opioid use disorder, BayMark also offers detoxification from a variety of addictive substances, including alcohol; and offers mental health services in select locations.

This study includes data from these BayMark Health Providers:

Healthcare Resource Centers
Recovery Services of New Mexico
Applegate Recovery
Middlesex Recovery
Now Available: BayMark's 2023 Treatment Outcomes ReportGet the Whitepaper
Now Available: BayMark's 2023 Treatment Outcomes ReportGet the Whitepaper